Origanum majorana L. extract effects on kidney tissue in STZ-induced DM rats

Elif Beyzanur Polat; Turgut Taşkın; Levent Kabasakal

Makale detayları

Origanum majorana L. extract effects on kidney tissue in STZ-induced DM rats

Yazarlar:

Elif Beyzanur Polat | Turgut Taşkın | Levent Kabasakal

Yayıncı:

Marmara University

Ana Başlıklar:

Medical Pharmacology

Dergi:

Journal of Research in Pharmacy Vol.27 Issue 4, pp.1638-1644

Belge Tipi:

Makale

Yayın Tarihi:

6/2025

Belge Dili:

İngilizce

Document ID (Org No.):

2001347861

pISSN:

2630-6344

Anahtar kelimeler:

Özet:

 Diabetes mellitus is a chronic disease characterized by decreased insulin synthesis or increased blood glucose due to insulin resistance. In this study, we aimed to investigate the protective role of Origanum majorana L. on the biochemical parameters of rats induced by streptozotocin STZ. Male Sprague-Dawley SD rats weighing 300-400 g were used. Rats were divided into 3 groups control, diabetes mellitus, and diabetes mellitus  Origanum majorana L. Citrate buffer was used i.p. in the control group. To induce experimental diabetes in rats, streptozotocin 60 mgkg was injected intraperitoneally i.p.. After 48 hours, rats with blood glucose values higher than 200 mgdL were considered diabetic. Diabetic rats were divided into two groups. While the first group was not treated, the second group received 200 mgkg of Origanum majorana L. extract for 6 weeks. In this study, Aspartate Aminotransferase AST, Alanine Aminotransferase ALT, and creatinine values were measured in serum. Malondialdehyde MDA and glutathione GSH levels were measured in kidney and liver tissues. It was found that AST, ALT, and creatinine values increased in diabetes and decreased significantly in the treatment group. MDA levels were increased and GSH values were decreased in diabetes. Origanum majorana L. treatment decreased lipid peroxidation and resulted in a significant increase in GSH levels. In conclusion, our findings show that Origanum majorana L. treatment has a protective effect against nephropathy in diabetes by preventing oxidative damage.

 Diabetes mellitus is a chronic disease characterized by decreased insulin synthesis or increased blood glucose due to insulin resistance. In this study, we aimed to investigate the protective role of Origanum majorana L. on the biochemical parameters of rats induced by streptozotocin STZ. Male Sprague-Dawley SD rats weighing 300-400 g were used. Rats were divided into 3 groups control, diabetes mellitus, and diabetes mellitus  Origanum majorana L. Citrate buffer was used i.p. in the control group. To induce experimental diabetes in rats, streptozotocin 60 mgkg was injected intraperitoneally i.p.. After 48 hours, rats with blood glucose values higher than 200 mgdL were considered diabetic. Diabetic rats were divided into two groups. While the first group was not treated, the second group received 200 mgkg of Origanum majorana L. extract for 6 weeks. In this study, Aspartate Aminotransferase AST, Alanine Aminotransferase ALT, and creatinine values were measured in serum. Malondialdehyde MDA and glutathione GSH levels were measured in kidney and liver tissues. It was found that AST, ALT, and creatinine values increased in diabetes and decreased significantly in the treatment group. MDA levels were increased and GSH values were decreased in diabetes. Origanum majorana L. treatment decreased lipid peroxidation and resulted in a significant increase in GSH levels. In conclusion, our findings show that Origanum majorana L. treatment has a protective effect against nephropathy in diabetes by preventing oxidative damage.

 Diabetes mellitus is a chronic disease characterized by decreased insulin synthesis or increased blood glucose due to insulin resistance. In this study, we aimed to investigate the protective role of Origanum majorana L. on the biochemical parameters of rats induced by streptozotocin STZ. Male Sprague-Dawley SD rats weighing 300-400 g were used. Rats were divided into 3 groups control, diabetes mellitus, and diabetes mellitus  Origanum majorana L. Citrate buffer was used i.p. in the control group. To induce experimental diabetes in rats, streptozotocin 60 mgkg was injected intraperitoneally i.p.. After 48 hours, rats with blood glucose values higher than 200 mgdL were considered diabetic. Diabetic rats were divided into two groups. While the first group was not treated, the second group received 200 mgkg of Origanum majorana L. extract for 6 weeks. In this study, Aspartate Aminotransferase AST, Alanine Aminotransferase ALT, and creatinine values were measured in serum. Malondialdehyde MDA and glutathione GSH levels were measured in kidney and liver tissues. It was found that AST, ALT, and creatinine values increased in diabetes and decreased significantly in the treatment group. MDA levels were increased and GSH values were decreased in diabetes. Origanum majorana L. treatment decreased lipid peroxidation and resulted in a significant increase in GSH levels. In conclusion, our findings show that Origanum majorana L. treatment has a protective effect against nephropathy in diabetes by preventing oxidative damage.

 Diabetes mellitus is a chronic disease characterized by decreased insulin synthesis or increased blood glucose due to insulin resistance. In this study, we aimed to investigate the protective role of Origanum majorana L. on the biochemical parameters of rats induced by streptozotocin STZ. Male Sprague-Dawley SD rats weighing 300-400 g were used. Rats were divided into 3 groups control, diabetes mellitus, and diabetes mellitus  Origanum majorana L. Citrate buffer was used i.p. in the control group. To induce experimental diabetes in rats, streptozotocin 60 mgkg was injected intraperitoneally i.p.. After 48 hours, rats with blood glucose values higher than 200 mgdL were considered diabetic. Diabetic rats were divided into two groups. While the first group was not treated, the second group received 200 mgkg of Origanum majorana L. extract for 6 weeks. In this study, Aspartate Aminotransferase AST, Alanine Aminotransferase ALT, and creatinine values were measured in serum. Malondialdehyde MDA and glutathione GSH levels were measured in kidney and liver tissues. It was found that AST, ALT, and creatinine values increased in diabetes and decreased significantly in the treatment group. MDA levels were increased and GSH values were decreased in diabetes. Origanum majorana L. treatment decreased lipid peroxidation and resulted in a significant increase in GSH levels. In conclusion, our findings show that Origanum majorana L. treatment has a protective effect against nephropathy in diabetes by preventing oxidative damage.

Makale detayları

Origanum majorana L. extract effects on kidney tissue in STZ-induced DM rats

Yazarlar: Elif Beyzanur Polat | Turgut Taşkın | Levent Kabasakal

Yayıncı: Marmara University

Ana Başlıklar: Medical Pharmacology

Dergi: Journal of Research in Pharmacy Vol.27 Issue 4, pp.1638-1644

Belge Tipi: Makale

Yayın Tarihi: 6/2025

Belge Dili: İngilizce

Document ID (Org No.): 2001347861

pISSN: 2630-6344

Diabetes mellitus

liver

kidney

Origanum majorana L.

oxidative damage

Sayı

Yazarlar:

Elif Beyzanur Polat | Turgut Taşkın | Levent Kabasakal

Yayıncı:

Marmara University

Ana Başlıklar:

Medical Pharmacology

Dergi:

Journal of Research in Pharmacy Vol.27 Issue 4, pp.1638-1644

Belge Tipi:

Makale

Yayın Tarihi:

6/2025

Belge Dili:

İngilizce

Document ID (Org No.):

2001347861

pISSN:

2630-6344